Carnegie Mellon researchers engineered 'AggreBots'—microscale living robots made from human lung cells capable of programmable motility—potentially enabling targeted drug delivery inside the body. Complementary advances in microdevice technology integrate AI-powered single-cell analysis facilitating high-throughput biomolecule delivery. These innovations exemplify the convergence of tissue engineering, robotics, and AI to develop next-generation biologically based therapeutic tools.